/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 1203 blog entries.

FDA approves Pfizer lung cancer drug

The FDA has approved Pfizer's LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for certain patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). “Over the years, Pfizer has transformed research, management and treatment for patients with ALK-positive non-small cell lung cancer. Building upon our extensive understanding of tumor complexity and treatment resistance, LORBRENA was discovered by Pfizer scientists and developed specifically to inhibit tumor mutations that may drive resistance to other ALK tyrosine kinase inhibitors,” said Andy Schmeltz, Global President, Pfizer Oncology. more

By |November 8th, 2018|News|0 Comments

Alexion reports deals with Dicerna, Syntimmune

Alexion and Dicerna have announced a collaboration  to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases. An RNAi-based approach to blocking the production of complement pathway factors offers the potential to inhibit the uncontrolled complement activation that leads to many diseases ... more Read article re the deal at FierceBiotech Separately, Alexion reports that the acquisition of Syntimmune has been successfully completed. The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with Immunoglobulin G (IgG) and IgG immune complexes with the potential [...]

By |November 8th, 2018|Uncategorized|0 Comments

Cybrexa expands Scientific Advisory Board

Cybrexa Therapeutics has expanded its Scientific Advisory Board with the appointments of Geoffrey Shapiro, M.D., Ph.D. Director, the Dana-Farber Cancer Institute and Timothy Yap MBBS, Ph.D., MRCP(UK), BSc (Hons), PgDip of The University of Texas MD Anderson Cancer Center. Cybrexa is a privately-held biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. Per Hellsund, President & CEO of Cybrexa, said, “Cybrexa is currently at a major inflection point as we rapidly move toward entering the clinic with the first candidate generated from our paradigm-changing [...]

By |November 8th, 2018|News|0 Comments

CARA names Joana Goncalves Chief Medical Officer

Cara Therapeutics has appointed Joana Goncalves, M.D. Chief Medical Officer. Dr. Goncalves brings more than 17 years of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Vice President, Medical Affairs for Dermatology and Neurology at Celgene Corporation. “We are very pleased to welcome Joana to the Cara team,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. more

By |November 8th, 2018|News|0 Comments

UConn researcher to study dyslexia mechanisms

University of Connecticut professor of psychological sciences Fumiko Hoeft has received more than $3 million from the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development to study how compensatory mechanisms work in the brain, and their connection to dyslexia. Hoeft will study the neural processes underlying linguistic and cognitive processes such as short-term memory and its impact on reading. She will use several neuroimaging methods to gain a deep understanding of compensatory mechanisms by measuring neurochemicals, cortical excitability, and functional and structural brain networks. more

By |November 8th, 2018|Uncategorized|0 Comments

Rallybio illustrates changing biopharma landscape

Farmington's Rallybio, founded by ex-Alexion employees, has already raised $37 million in its quest to identify drug targets that will treat ultra-rare diseases. It's the type of venture Connecticut's Department of Economic and Community Development would like to see more of. For although Connecticut biopharma has been through several downsizing waves, that may be a good thing, because it fosters the environment in which innovation can occur. Note: The article linked to below describes the ebb and flow pattern typical of companies in the bioscience industry. The good news is that Connecticut is doing a better job than many at retaining talent in the [...]

By |November 8th, 2018|News|0 Comments

BioCT welcomes new member SphereGen Technologies

SphereGen Technologies is a Microsoft Gold Partner Application Development, a Mixed Reality Partner and a Cloud Solution Provider. Its aim is to make the integration and exchange of critical business information easy. more

By |November 8th, 2018|News|0 Comments

Melinta appoints John H. Johnson interim CEO

Melinta Therapeutics has appointed John H. Johnson interim chief executive officer, (CEO), succeeding Dan Wechsler, who is stepping down to pursue other opportunities. Johnson has more than 30 years of biopharmaceutical industry, executive leadership and commercial experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone and Pfizer, Inc. “On behalf of the board of directors, we would like to thank Dan Wechsler for his contributions to the Company and we wish him well in his future endeavors,” said Kevin Ferro, chairman of Melinta Therapeutics. more

By |November 8th, 2018|News|0 Comments

BioCT welcomes new member Rebiotix

Rebiotix, a subsidiary of the Ferring Pharmaceuticals Group, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome. The company's Microbiota Restoration Therapy™ drug platform delivers live, human-derived microbes into a sick patient’s intestinal tract to treat disease. more

By |November 8th, 2018|News|0 Comments

Rallybio named to ‘Fierce 15’ biotech list

Rallybio has been named to the 'Fierce 15' list of biotech companies by the industry online pubication FierceBiotech. “We all feel that we’ve got several more medicines left in us,” say Rallybio's founders, the Alexion veterans Martin Mackay, Stephen Uden, and Jeffrey Fryer. The team recently raised $37 million in funding to focus on developing new drugs for rare diseases. more

By |October 26th, 2018|News|0 Comments